- Home
- FSHP vs CHRS Comparison
FSHP vs CHRS Comparison
Compare FSHP & CHRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FSHP
- CHRS
- Stock Information
- Founded
- FSHP 2018
- CHRS 2010
- Country
- FSHP United States
- CHRS United States
- Employees
- FSHP N/A
- CHRS N/A
- Industry
- FSHP
- CHRS Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- FSHP
- CHRS Health Care
- Exchange
- FSHP NYSE
- CHRS Nasdaq
- Market Cap
- FSHP 92.7M
- CHRS 102.0M
- IPO Year
- FSHP 2024
- CHRS 2014
- Fundamental
- Price
- FSHP $10.49
- CHRS $0.97
- Analyst Decision
- FSHP
- CHRS Buy
- Analyst Count
- FSHP 0
- CHRS 3
- Target Price
- FSHP N/A
- CHRS $4.68
- AVG Volume (30 Days)
- FSHP 5.4K
- CHRS 1.3M
- Earning Date
- FSHP 01-01-0001
- CHRS 08-07-2025
- Dividend Yield
- FSHP N/A
- CHRS N/A
- EPS Growth
- FSHP N/A
- CHRS N/A
- EPS
- FSHP 0.21
- CHRS N/A
- Revenue
- FSHP N/A
- CHRS $272,251,000.00
- Revenue This Year
- FSHP N/A
- CHRS N/A
- Revenue Next Year
- FSHP N/A
- CHRS $99.43
- P/E Ratio
- FSHP $49.31
- CHRS N/A
- Revenue Growth
- FSHP N/A
- CHRS 19.87
- 52 Week Low
- FSHP $9.99
- CHRS $0.66
- 52 Week High
- FSHP $10.49
- CHRS $2.43
- Technical
- Relative Strength Index (RSI)
- FSHP N/A
- CHRS 57.25
- Support Level
- FSHP N/A
- CHRS $0.88
- Resistance Level
- FSHP N/A
- CHRS $1.15
- Average True Range (ATR)
- FSHP 0.00
- CHRS 0.07
- MACD
- FSHP 0.00
- CHRS 0.01
- Stochastic Oscillator
- FSHP 0.00
- CHRS 45.95
About FSHP FLAG SHIP ACQUISITION CORPORATION
Flag Ship Acquisition Corp is a blank check company formed to effect a merger, share exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses.
About CHRS Coherus BioSciences Inc.
Coherus Oncology Inc is a fully integrated commercial-stage inventive oncology company with an approved next-generation PD-1 inhibitor, LOQTORZI, and a pipeline that includes two mid-stage clinical candidates targeting liver, lung, head & neck, and other cancers. Its strategy is to expand the use of LOQTORZI in NPC and advance the development of new indications for LOQTORZI in combination with both its pipeline candidates as well as its industry partners, driving synergies from proprietary combinations, including first-in-class anticancer agents. Its portfolio includes LOQTORZI, CHS-114, and Casdozokitug.